|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Monday
MBP8298 shown to safely delay disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. BioMS Medical to present at the 22nd Congress of the European Com mittee for Treatment and Research in Multiple Sclerosis (ECTRIMS) :
"MBP8298 shown to safely delay disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Phase II and long-term follow-up treatment data to be presented at ECTRIMS - MBP8298 shown to safely delay disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. - Pivotal Phase II/III clinical trial underway in Europe and Canada - .....MORE" |